Flow-mediated dilation (FMD) is the standard tool used to assess endothelial function. The premise behind the standard FMD test is that it serves as an endothelial-dependant nitric oxide bioassay; however, the endothelium may release additional dilatory molecules which contribute to FMD, most notably prostacyclin and endothelial-derived hyperpolarizing factor. The relative importance of these molecules to the dilatory response may vary substantially among individuals, particularly in response to a number of diseased states. This review discusses how each of these molecules may contribute to vasodilation, and considers the circumstances in which they may vary.
Introduction
The pathological complications of atherosclerosis, namely myocardial infarction and strokes, remain the leading cause of mortality in the Western world 1) . Endothelial dysfunction precedes atherosclerosis, and disruption of this essential monolayer occurs early in the pathogenesis of cardiovascular disease (CVD) [2] [3] [4] . The flow-mediated dilation (FMD) test is the standard non-invasive tool used to assess endothelial function 5) . Reduced FMD is an early marker of atherosclerosis 5) and has been noted for its capacity to predict future cardiovascular disease events [6] [7] [8] .
The principle behind the FMD test is that it serves as a nitric oxide (NO) bioassay [9] [10] [11] [12] . NO performs a myriad of anti-atherogenic functions and is considered the most important molecule governing endothelial function and health [13] [14] [15] [16] ; however, the endothelium can release additional dilatory molecules which may contribute to FMD, most notably prostacyclin (PGI2) 9) and endothelial-derived hyperpolarizing factor (EDHF) 17, 18) . The relative importance of these molecules varies by vascular bed and among individuals, particularly individuals exhibiting a number of a diseased states [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . As well as dilatory molecules, the endothelium releases endothelial-derived constrictor factors, including endothelin-1 and angiotensin Ⅱ, which have been shown to be altered with aging 29, 30) , diseased states [31] [32] [33] [34] [35] and inactivity [36] [37] [38] . As such, the FMD response represents an interplay between these endothelial-derived vasodilator and constrictor factors 32, 39, 40) . The application of the FMD test is widely reported in the literature. A search of the PubMed database yielded 484 articles for the year 2010 alone when using the following keywords: flow-mediated dilation; flow-mediated dilatation; flow-mediated vasodilation. Among these articles, 100 were classified as clinical trials, which included pharmaceutical trials specifically targeting nitric oxide synthesis (NOS)-dependent pathways (see recent meta-analysis by Inaba et al. 6 ) for a summary of articles using FMD to FMD on an intact endothelium was subsequently shown to occur in large-conduit arteries as well as in resistance vessels 75) . In 1986, Furchgott and Ignarro et al. 76) proposed that the mediator involved in endothelium-dependent relaxation is NO. Moncada and colleagues 77, 78) confirmed that NO is the major endothelium-derived relaxing factor; by providing the scientific community with inhibitors of NOS 79, 80) , they made the exploration of the physiological role of NO possible. NO is a biologically active and volatile gas that is present in practically all tissue. Due to its low molecular weight and lipophilic properties, it diffuses easily across cell membranes. NO in vascular tissue is likely activated through one of two pathways: i) endothelial NOS (eNOS) or ii) neuronal NOS (nNOS).
Vasodilatory Mechanism
In response to shear stress, cell signaling events lead to an elevation in endothelial cell cytosolic calcium (Ca 2＋ ), which binds to the regulatory protein calmodulin 81) (see Fig. 1 ). Calcium displaces the inhibitor caveolin-1 from calmodulin (CaM), allowing Ca
2＋
-CaM access to eNOS. The enzymatic actions of eNOS lead to NO synthesis in endothelial cells from its precursor, L-arginine 82) . NO diffuses across the endothelial intima, reaches the smooth muscle cells, and then stimulates soluble guanylate cyclasecatalyzed production of cyclic guanosine monophosphate (cGMP) 83, 84) . cGMP down-regulates the contractile process by antagonizing Ca 2＋ release from the sarcoplasmic reticulum, its entry through Ca 2＋ channels, and by inhibiting the Ca 2＋ activated contractile process itself 85, 86) . While Ca 2＋ -CaM-dependent eNOS activation is the likely primary pathway responsible for NO production, other pathways do exist. Studies show that NO released from nNOS localized in neurons lining coronary and pial arteries can mediate flow-and agonist-induced dilations in eNOS knockout mice [87] [88] [89] . This suggests that a compensatory interaction between eNOS and nNOS could offset eNOS deficiencies; however, more work is required to clarify the relative role of nNOS-derived NO in vessels with competent eNOS.
Response to Shear Stress
NO is released from endothelial cells continuously while cells are activated 90, 91) and, owing to the high Ca 2＋ sensitivity of CaM, NO is up-regulated rapidly in response to increases in shear stress 92, 93) . In healthy arteries, NO is therefore important for maintaining basal tone, as well as regulating tone in response to short-term increases in shear stress 94) . predict cardiovascular events). The efficacy of this test is limited without comprehension of the possible mechanisms contributing to FMD. The purpose of this review is to discuss the relative importance of NO, PGI2 and EDHF to FMD.
Flow-Mediated Dilation
A number of authors have developed standardized guidelines for conducting FMD [41] [42] [43] , including recent articles by Thijssen et al. 44) and Stoner et al. 45) . Although the brachial artery is the common measurement site for FMD, conduit arteries such as the posterior tibial 46, 47) , popliteal 48, 49) , and femoral arteries [50] [51] [52] have been employed more recently to examine endothelial function. The standard FMD test, as first described by Celermajer et al. 53) , places a pneumatic forearm tourniquet just below the elbow distal to the imaged brachial artery. The tourniquet is inflated to a supra-systolic blood pressure for five minutes. Rapid deflation of the tourniquet instigates increased blood flow (reactive hyperemia) to the oxygen-starved forearm muscles, with a subsequent increase in flow through the upstream brachial artery. The flowinduced increase in shear stress results in vasodilation of the brachial artery. The magnitude of FMD, expressed as the percentage increase in diameter above rest, is used to represent endothelial health.
Despite the term flow-mediated dilation, shear stress is the established stimulus for FMD 9, [54] [55] [56] [57] [58] [59] [60] [61] . Shear stress is determined by red blood cells moving close to endothelial cells. As the fluid particles "travel" through the lumen, their velocity increases from zero at the vessel wall to a maximum value at the center of the vessel. This leads to the establishment of a gradient, which is defined as shear stress. Shear stress therefore acts at a tangent to the wall to create a frictional force at the surface of the endothelium. As endothelial cells are equipped with mechanosensors to detect this stress [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] , the vascular tissues respond accordingly with acute adjustments in vascular tone 72) . This vasodilatory response reflects alterations in the rate of production of endothelial-derived mediators, including NO, PGI2 and EHRF, which act locally to modulate vascular smooth muscle tone.
Nitric Oxide
In 1970, Rodbard 73) proposed that the endothelium may sense and respond to shear stress generated by flowing blood. In 1980, Furchgott and Zawadski 74) discovered that agonist-mediated vasodilation requires participation of the endothelium. The dependence of injury 20) , congestive heart failure 21) , hypercholesterolemia 22) , and angioplasty 23) . Furthermore, studies have shown that the proportional contribution of NO to FMD is diminished when conduit arteries are exposed to prolonged increases in shear stress. This has been demonstrated via the use of occlusion periods greater than 5 minutes, or through local hand warming 98) .
Prostacyclin
Flow-induced PGI2 changes were one of the earliest documented responses of endothelial cells to shear stress 102) . Similar to NO, PGI2 is secreted by endothelial cells lining blood vessels where it not only serves as a potent vasodilator 103) , but also inhibits platelet aggregation 104) , which helps to prevent atherosclerosis and subsequent thrombosis 105, 106) . PGI2 and Relative Contribution to Flow-Mediated Dilation Doshi et al. 94) found that administration of NOS inhibitor N G -monomethyl-L-arginine (L-NMMA) completely abolished FMD of the brachial artery following 5 minutes of wrist cuff occlusion, with no difference in the hyperemic stimulus; however, L-NMMA does not completely block the FMD response when the occlusion cuff is placed on the upper arm 94, 95) (see Table 1 ). Similarly, L-NMMA does not completely abolish FMD in the radial 11, 27, 28, [96] [97] [98] [99] [100] [101] and femoral arteries 12) . The relative importance of NO to FMD may also be altered when conducting this test on patients with a number of diseased states, such as dystonia 26) , chronic heart failure 27) or hypertension 28) (see Table 2 ). These findings are supported by animal studies, which have found NO to be down-regulated following ischemia-reperfusion injury 19) , mild head (1) Blood flowing through an artery creates a shearing stress at the endothelial surface. A composite of superimposed concentric circles is shown in 1a (i.e., transverse plane) to correspond with the gradient of increasing RBC velocity from the periphery to the center of the lumen. RBC velocity is represented as a parabola (i.e., longitudinal plane) in 1b using the same color coding as in 1a. The magnitude of the parabola (left to right) corresponds with the gradient of increasing RBC velocity from the periphery to the center of the lumen. the femoral artery in humans during prolonged steady-state exercise 111) . In the radial artery, conflicting findings have been reported. PGI is not thought to play a role in FMD during both sustained and nonsustained flow stimulations under physiological conditions 11, 100) . Similar findings were reported by Markwald et al. 112) , who found that neither NO nor PGs were obligatory in the normal local vasodilatory response to steady-state hypoxia; however, combined inhibition of NO and PGs abolished the vasodilatory response to steady-state hypoxia.
Some of the ambiguity regarding the role of PGI2 in FMD may be explained by two factors: i) at least some portion of PGI2-mediated vasodilation is, in fact, NO dependent 113) and ii) in healthy conduit arteries NO has an inhibitory effect on PGI2 secretion 109) . Indeed, Osani et al. 109) showed that inhibition of eNOS enhanced the production of PGI2 in response to shear stress, indicating that endogenous NO functions as an inhibitor of PGI2 production in an autocrine or paracrine fashion. This finding has been reported elsewhere [114] [115] [116] [117] . The importance of PGI2 to conduit vessel dilation may also be altered with various diseased states and aging. Normotensive young subjects do not produce significant amounts of vasoactive PGIs, in contrast to hypertensive or older humans [118] [119] [120] . In vivo, NO are arguably the most important cardio-protective mechanisms yet described.
Vasodilatory Mechanism
PGI2 is a major metabolic derivative of arachidonic acid (AA). AA is liberated by the actions of phospholipase A2 (PLA2) through a Ca 2＋ -dependent step, and sequentially converted by the activity of cyclooxygenase (COX) 107, 108) (see Fig. 1 ). PGI2 elicits smooth muscle relaxation by stimulating adenylyl cyclase and production of cyclic adenosine monophosphate.
Response to Shear Stress
When endothelial cells are stimulated by shear stress, the subsequent increase in intracellular Ca 2＋ results in the co-release of NO and PGI2 93) . Ca 2＋ is a rate-limiting step and explains the different kinetics of release of these two hormones. PLA2 activation requires a high Ca 2＋ burst whereas eNOS has a lower requirement for Ca 2＋ 92, 93) . In healthy conduit arteries NO has an inhibitory effect on PGI2 secretion 109) .
Relative Contribution to Flow-Mediated Dilation NO and prostanoids (PGs) have been shown to contribute to FMD in the human coronary circulation following metabolic stimulation 110) . Conversely, NO and PGI demonstrate a modest role in FMD of 94) Agewall et al. 146) Doshi et al. 94) Lieberman et al. 95) Joannides et al.
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Kooijman et al. 125) , lipoxygenase products 126) , and reactive oxygen species (e.g., H2O2) 127) .
Response to Shear Stress
In human resistance arteries, EDHF contributes to basal tone and endothelium-mediated dilation in response to pharmacological stimulation 128, 129) . Although investigation into the role of EDHF in human conduit arteries has been limited, it has been demonstrated that EDHF inhibition with tetraethylammonium (TEA, nonselective K ＋ channel inhibitor) decreases basal radial artery tone as well as the vasodilatory response to sustained increases in shear stress through local hand warming 130, 131) . The vasodilatory response to local hand warming is decreased to a greater extent when TEA is combined with L-NMMA than when either of these inhibitors are infused independently. This supports the suggestion that there is cross-talk between EDHF and NO [130] [131] [132] .
Relative Contribution to Flow-Mediated Dilation
Although variability between species and vascular beds is observed, EDHF-mediated contribution to FMD increases as the vessel size decreases 133) , with EDHF playing a prominent role in the resistance vessels of the microcirculation 134) . Since EDHF's contribution is greatest at the level of small arteries, the actions of EDHF are of critical importance for the regulation of organ blood flow, peripheral vascular resistance and blood pressure. This is particularly evident when NO production is compromised 135) . In healthy conduit arteries, the degree to which EDHF contributes to relaxation may be small or nonexistent since NO inhibits the formation or action of EDHF 136) . Indeed, some studies have only demonstrated EDHF responses once NO production had been inhibited 132) . Bellien et al. 130, 131) examined the clinical studies have also shown that NO production was impaired in patients with atherosclerosis 121) , whereas PGI2 production was not reduced 25) . Ageing is associated with a shift away from PGI2-mediated vasodilatation to PGI2-mediated vasoconstriction (via thromboxane) 119) . For example, infusion of a COX inhibitor has little effect on acetylcholine-mediated dilatation in young adults, but actually enhances vasodilatation in older adults 119) . Further research is required in order to specifically identify the importance of PGI2 to FMD with aging and various diseased states.
Endothelium-Derived Hyperpolarizing Factor
In addition to NO and PGI2, it has been proposed that at least one additional endothelium-dependent process is responsible for relaxing vascular smooth muscle 17, 18) . This process is characterized by essential hyperpolarization of the vascular smooth muscle. The mediator is known as endothelium-derived hyperpolarizing factor (EDHF) 17, 18) . Unlike its predecessor, which required approximately six years before conclusively being identified as NO, the mechanism[s] of EDHF remain controversial 17, 18) . The elusive nature of EDHF is likely due to the fact that there are several EDHFs or mechanisms by which the endothelium can hyperpolarize vascular smooth muscle 17) .
Vasodilatory Mechanism
EDHF is defined as a dilator that: i) requires the endothelium, ii) is distinct from both endotheliumderived NOS (e.g., NO) or COX metabolites (e.g., PGI2), iii) dilates by hyperpolarizing the vascular smooth muscle, and iv) involves potassium (K ＋ ) channel activation, most often Ca 2＋ -activated K ＋ channels 122) . Several molecules or mediators that might act as EDHF have been identified, including K ＋ 123) , cytochrome P450 metabolites 124) , C-type natriuretic pep- Mayah et al.
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Owens et al. 147) CHD = chronic heart disease; CHF = chronic heart failure; HT = hypertension; L-NMMA = NG-monomethyl-L-arginine; SCI = spinal cord injury; SFA = superficial femoral artery; SVG = saphenous vein graft. dent 94) , provides a better prognosis for CVD risk. Further study is needed to confirm these findings and determine: i) which methodology and vessel (e.g., brachial or radial) provides the greatest prognostic strength, and ii) whether the prognostic strength for a given vessel is equal for all populations.
Discussion and Conclusions
The contributions of NO, PGI2, and EDHF to endothelium-dependent dilation are difficult to define as their importance may vary by vessel type and size, by disease state, and by the agonist chosen to stimulate the endothelium [140] [141] [142] [143] . Isolating the predominant mechanism is challenging, since a redundancy in endothelial dilator mechanisms, or interaction, has been demonstrated. For example, in cultured endothelial cells, inhibition of NOS or COX enzymes causes increased production of the non-blocked substance 109) . Conversely, the relative importance of EDHF in mediating dilation may be overestimated during combined NOS and COX inhibition due to normal suppression of the EDHF effects when NOS activity is intact 144, 145) . However, there is convincing evidence that NO is the primary mechanism responsible for FMD when: i) the subjects are healthy and free of disease, ii) the ischemic period is no longer than 5 minutes, and iii) ischemia is created using distal cuff placement. The contribution of NO to FMD may be down-regulated when subjects exhibit a number of diseased states (e.g., dystonia, chronic heart failure, or hypertension) or when a non-standardized FMD protocol is used (e.g., an artery other than the brachial, proximal cuff placement or prolonged ischemia).
The aforementioned factors do not necessarily limit the viability of the FMD test. NO is not the only important anti-atherogenic molecule released by the endothelium. The health of the endothelium remains an important construct, irrespective of the molecule[s] performing the many important functions served by this essential monolayer; however, an understanding of the dilatory pathways is important for interventions designed to improve vascular health, particularly those targeting the eNOS-dependant NO pathway.
A number of pharmaceuticals (including statins and angiotensin antagonists) demonstrate cardio-protective effects by improving endothelial NO bioavailability; however, it remains to be determined whether enhancing EDHF and PGI2 in conditions with impaired NO activity would be of therapeutic value, or whether agents that improve endothelial dysfunction may also enhance PGI2 and EDHF bioactivity. It contributions of NO and EDHF to sustained radial artery FMD. The radial artery diameter-shear stress relationship was shifted downward by L-NMMA, TEA, fluconazole (cytochrome P450 inhibitor), and, in a more pronounced manner, by the combinations of L-NMMA with TEA or with fluconazole.
EDHF may act as a backup endothelium-derived vasodilator when NO production is compromised. Experimental evidence indicates that a shift away from NO-mediated endothelium-dependent relaxation towards EDHF-dependent relaxation occurs in certain disease states 21, 137) . In the human forearm of hypertensive subjects, FMD is maintained despite decreased NO bioavailability because of the compensatory increased activity of EDHF 124, 138) . Similarly, Miura et al. 139) have reported that EDHF contributes more to FMD in human coronary arterioles in patients with coronary artery disease (CAD) than in individuals without CAD. EDHF has also been shown to be unregulated in ischemia-reperfusion injury 19) , mild head injury 20) , congestive heart failure 21) , hypercholesterolemia 22) , and angioplasty 23) . Further research is required in order to determine the importance of EDHF to FMD in the brachial artery in various diseased states and aging.
Does FMD Predict CVD Irrespective of the Vasodilatory Mechanisms Recruited ?
Inaba et al. 6 ) assessed the prognostic strength of FMD by conducting a meta-analysis of fourteen observational studies (n = 5,547) that examined the association between brachial artery FMD and future cardiovascular events. Adjusting for confounding risk factors, a 1% increase in brachial artery FMD was associated with a relative risk of 0.87. This equates to a 13% (95% CI, 9%-17%) reduction in the risk of future cardiovascular events.
More recently, Green et al. 10) re-analyzed the meta-analysis conducted by Inaba and colleagues 6) by assessing the prognostic strength of those studies that used distal versus proximal cuff placement. For studies in which distal cuff placement was selected (the standard and widely advocated approach), a 1% increase in FMD was associated with a relative risk of 0.91, that is, a 9% (95% CI: 4% to 13%) decrease in the future risk of cardiovascular events. For studies involving proximal cuff placement, the relative risk improved to 0.83, that is, a 17% (95% CI: 12% to 22%) decrease in cardiovascular risk for every 1% increase in FMD. The difference between these two relative risks was found to be statistically significant, and indicated that FMD conducted using proximal cuff placement, which has been demonstrated to be less NO-depen- also remains to be determined whether the standard brachial artery FMD protocol is the most appropriate choice for trials targeting specific endothelium-dependent pathways. Furthermore, it is unknown whether CVD prognosis can improved by: (1) measuring FMD at multiple anatomical locations, and (2) combining proximal and distal cuff placements. 
